Mitochondrial Oxidative Stress and Calcium-Dependent Permeability Transition are Key Players in the Mechanisms of Statins-Associated Side Effects
暂无分享,去创建一个
[1] A. Vercesi,et al. Pravastatin Chronic Treatment Sensitizes Hypercholesterolemic Mice Muscle to Mitochondrial Permeability Transition: Protection by Creatine or Coenzyme Q10 , 2017, Front. Pharmacol..
[2] E. Björnsson. Hepatotoxicity of statins and other lipid‐lowering agents , 2017, Liver international : official journal of the International Association for the Study of the Liver.
[3] J. Wise. High intensity statins are associated with greatest reduction in mortality , 2016, British Medical Journal.
[4] V. Jamdade,et al. Statin use and the risk of developing diabetes: a network meta‐analysis , 2016, Pharmacoepidemiology and Drug Safety.
[5] C. Stephens,et al. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. , 2016, Journal of hepatology.
[6] M. Davidson,et al. The Risk of Hepatotoxicity, New Onset Diabetes and Rhabdomyolysis in the Era of High-Intensity Statin Therapy: Does Statin Type Matter? , 2016, Progress in cardiovascular diseases.
[7] T. R. Figueira,et al. The Contribution of Nicotinamide Nucleotide Transhydrogenase to Peroxide Detoxification Is Dependent on the Respiratory State and Counterbalanced by Other Sources of NADPH in Liver Mitochondria* , 2016, The Journal of Biological Chemistry.
[8] Jianming Cai,et al. Changes in carotid plaque tissue composition in subjects who continued and discontinued statin therapy. , 2016, Journal of clinical lipidology.
[9] A. Jemal,et al. Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group , 2016, International journal of cancer.
[10] E. Gill,et al. Statins and the Liver. , 2016, Endocrinology and metabolism clinics of North America.
[11] H. Oliveira,et al. Chronic use of pravastatin reduces insulin exocytosis and increases β-cell death in hypercholesterolemic mice. , 2016, Toxicology.
[12] D. Betteridge,et al. The diabetogenic action of statins — mechanisms and clinical implications , 2016, Nature Reviews Endocrinology.
[13] F. Santilli,et al. Oxidative stress in chronic vascular disease: From prediction to prevention. , 2015, Vascular pharmacology.
[14] S. Azar,et al. The Safety and Benefit of Statins in Liver Cirrhosis: a Review. , 2015, Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association.
[15] U. Saxena,et al. Simvastatin may induce insulin resistance through a novel fatty acid mediated cholesterol independent mechanism , 2015, Scientific Reports.
[16] R. Rodenburg,et al. Statin-Induced Myopathy Is Associated with Mitochondrial Complex III Inhibition. , 2015, Cell metabolism.
[17] L. Ferder,et al. Inflammation, oxidative stress and renin angiotensin system in atherosclerosis. , 2015, World journal of biological chemistry.
[18] Manzoor Ahmad Sofi,et al. Oxidative stress, mitochondrial dysfunction and neurodegenerative diseases; a mechanistic insight. , 2015, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[19] P. Dabla,et al. Oxidative stress and antioxidants in hypertension-a current review. , 2015, Current hypertension reviews.
[20] Zhichong Wang,et al. Increased Oxidative Stress as a Selective Anticancer Therapy , 2015, Oxidative medicine and cellular longevity.
[21] C. F. Andrade,et al. Oxidative Stress and Lung Ischemia-Reperfusion Injury , 2015, Oxidative medicine and cellular longevity.
[22] A. Sikorski,et al. The effect of statins on cancer cells—review , 2015, Tumor Biology.
[23] K. Maiese. New Insights for Oxidative Stress and Diabetes Mellitus , 2015, Oxidative medicine and cellular longevity.
[24] Dean P. Jones. Redox theory of aging , 2015, Redox biology.
[25] M. Laakso,et al. Increased risk of diabetes with statin treatment is associated with impaired insulin sensitivity and insulin secretion: a 6 year follow-up study of the METSIM cohort , 2015, Diabetologia.
[26] R. Andrade,et al. Acute liver failure following atorvastatin dose escalation: is there a threshold dose for idiosyncratic hepatotoxicity? , 2015, Journal of hepatology.
[27] Lawrence A Leiter,et al. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management , 2015, European heart journal.
[28] A. Vogt. The genetics of familial hypercholesterolemia and emerging therapies , 2015, The application of clinical genetics.
[29] A. Gastaldelli,et al. The good and bad effects of statins on insulin sensitivity and secretion , 2014, Endocrine research.
[30] Jiezhun Gu,et al. Spectrum of statin hepatotoxicity: Experience of the drug‐induced liver injury network , 2014, Hepatology.
[31] D. Barrett,et al. Translational insight into statin-induced muscle toxicity: from cell culture to clinical studies. , 2014, Translational research : the journal of laboratory and clinical medicine.
[32] M. Ristow,et al. Unraveling the Truth About Antioxidants: Mitohormesis explains ROS-induced health benefits , 2014, Nature Medicine.
[33] N. Sattar,et al. The use of statins in people at risk of developing diabetes mellitus: evidence and guidance for clinical practice. , 2014, Atherosclerosis. Supplements.
[34] R. Andrade,et al. Hepatotoxicity associated with statin use: analysis of the cases included in the Spanish Hepatotoxicity Registry. , 2014, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[35] J. C. Díaz-Zagoya,et al. Coenzyme Q10 supplementation improves metabolic parameters, liver function and mitochondrial respiration in rats with high doses of atorvastatin and a cholesterol-rich diet , 2014, Lipids in Health and Disease.
[36] A. Vercesi,et al. A spontaneous mutation in the nicotinamide nucleotide transhydrogenase gene of C57BL/6J mice results in mitochondrial redox abnormalities. , 2013, Free radical biology & medicine.
[37] L. Kopelovich,et al. Inhibition of Proliferation and Induction of Autophagy by Atorvastatin in PC3 Prostate Cancer Cells Correlate with Downregulation of Bcl2 and Upregulation of miR-182 and p21 , 2013, PloS one.
[38] M. Bisoffi,et al. Ubiquinol rescues simvastatin-suppression of mitochondrial content, function and metabolism: implications for statin-induced rhabdomyolysis. , 2013, European journal of pharmacology.
[39] R. Heidari,et al. Mechanisms of the Statins Cytotoxicity in Freshly Isolated Rat Hepatocytes , 2013, Journal of biochemical and molecular toxicology.
[40] L. Bujanda,et al. Several statins increase body and liver fat accumulation in a model of metabolic syndrome. , 2013, Journal of physiology and pharmacology : an official journal of the Polish Physiological Society.
[41] A. Vercesi,et al. Protection of rat skeletal muscle fibers by either L-carnitine or coenzyme Q10 against statins toxicity mediated by mitochondrial reactive oxygen generation , 2013, Frontiers in Physiology.
[42] R. Igić,et al. Simvastatin-lnduced nocturnal leg pain disappears with pravastatin substitution. , 2013, Srpski arhiv za celokupno lekarstvo.
[43] A. Camargo,et al. Mitochondria as a source of reactive oxygen and nitrogen species: from molecular mechanisms to human health. , 2013, Antioxidants & redox signaling.
[44] S. Javadov,et al. Mitochondrial Permeability Transition and Cell Death: The Role of Cyclophilin D , 2013, Front. Physiol..
[45] C. Kwak,et al. Simvastatin induces apoptosis in castrate resistant prostate cancer cells by deregulating nuclear factor-κB pathway. , 2013, The Journal of urology.
[46] A. Vercesi,et al. Protective effects of l-carnitine and piracetam against mitochondrial permeability transition and PC3 cell necrosis induced by simvastatin. , 2013, European journal of pharmacology.
[47] A. Goc,et al. Simultaneous modulation of the intrinsic and extrinsic pathways by simvastatin in mediating prostate cancer cell apoptosis , 2012, BMC Cancer.
[48] Christos Hatzigeorgiou,et al. Effect of coenzyme Q10 supplementation on statin-induced myalgias. , 2012, The American journal of cardiology.
[49] S. Marcella,et al. Statin use and fatal prostate cancer , 2012, Cancer.
[50] U. Moll,et al. p53 Opens the Mitochondrial Permeability Transition Pore to Trigger Necrosis , 2012, Cell.
[51] O. Augusto,et al. Connecting the chemical and biological properties of nitric oxide. , 2012, Chemical research in toxicology.
[52] M. Parihar,et al. Statins lower calcium-induced oxidative stress in isolated mitochondria , 2012, Human & experimental toxicology.
[53] E. Cadenas,et al. Silencing of nicotinamide nucleotide transhydrogenase impairs cellular redox homeostasis and energy metabolism in PC12 cells. , 2012, Biochimica et biophysica acta.
[54] P. Sirvent,et al. Muscle mitochondrial metabolism and calcium signaling impairment in patients treated with statins. , 2012, Toxicology and applied pharmacology.
[55] B. Tomlinson,et al. Safety of statins: an update , 2012, Therapeutic advances in drug safety.
[56] Evangelos Kalaitzakis,et al. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. , 2012, Journal of hepatology.
[57] A. Malfitano,et al. Pharmacological Actions of Statins: A Critical Appraisal in the Management of Cancer , 2012, Pharmacological Reviews.
[58] R. Newman,et al. Differential Effects of Pravastatin and Simvastatin on the Growth of Tumor Cells from Different Organ Sites , 2011, PloS one.
[59] J. L. Olin,et al. 3-hydroxyl-3-methylglutaryl coenzyme A reductase inhibitor use in chronic liver disease: a therapeutic controversy. , 2011, Journal of clinical lipidology.
[60] Y. Saito,et al. Pitavastatin: an overview. , 2011, Atherosclerosis. Supplements.
[61] M. Lucena,et al. Recurrent drug-induced liver injury (DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. , 2011, Journal of hepatology.
[62] H. Lee,et al. Prevention of free fatty acid‐induced hepatic lipotoxicity by carnitine via reversal of mitochondrial dysfunction , 2011, Liver international : official journal of the International Association for the Study of the Liver.
[63] S. Dikalov. Cross talk between mitochondria and NADPH oxidases. , 2011, Free radical biology & medicine.
[64] D. Albanes,et al. Serum total and HDL cholesterol and risk of prostate cancer , 2011, Cancer Causes & Control.
[65] Joanna M. Young,et al. Relationship between plasma coenzyme Q10, asymmetric dimethylarginine and arterial stiffness in patients with phenotypic or genotypic familial hypercholesterolemia on long-term statin therapy. , 2011, Atherosclerosis.
[66] Grant T. Generaux,et al. Impact of SLCO1B1 (OATP1B1) and ABCG2 (BCRP) genetic polymorphisms and inhibition on LDL-C lowering and myopathy of statins , 2011, Xenobiotica; the fate of foreign compounds in biological systems.
[67] S. Czuczwar,et al. Statin-induced myopathies , 2011, Pharmacological reports : PR.
[68] V. Mootha,et al. Integrative genomics identifies MCU as an essential component of the mitochondrial calcium uniporter , 2011, Nature.
[69] R. Rizzuto,et al. A forty-kilodalton protein of the inner membrane is the mitochondrial calcium uniporter , 2011, Nature.
[70] A. Mattiello-Sverzut,et al. Characterization of Fiber Types in Different Muscles of the Hindlimb in Female Weanling and Adult Wistar Rats , 2011, Acta histochemica et cytochemica.
[71] A. Morris,et al. Common Nonsynonymous Substitutions in SLCO1B1 Predispose to Statin Intolerance in Routinely Treated Individuals With Type 2 Diabetes: A Go‐DARTS Study , 2011, Clinical pharmacology and therapeutics.
[72] William M. Lee,et al. Drug‐induced acute liver failure: Results of a U.S. multicenter, prospective study , 2010, Hepatology.
[73] G. Hajnóczky,et al. Calcium Signalling: Fishing Out Molecules of Mitochondrial Calcium Transport , 2010, Current Biology.
[74] R. Hamanaka,et al. Mitochondrial reactive oxygen species regulate cellular signaling and dictate biological outcomes. , 2010, Trends in biochemical sciences.
[75] C. Vargas,et al. Simvastatin treatment prevents oxidative damage to DNA in whole blood leukocytes of dyslipidemic type 2 diabetic patients , 2010, Cell biochemistry and function.
[76] P. Bernardi,et al. Signal transduction to the permeability transition pore , 2010, FEBS letters.
[77] A. Endo. A historical perspective on the discovery of statins , 2010, Proceedings of the Japan Academy. Series B, Physical and biological sciences.
[78] U. Laufs,et al. Pleiotropic effects of statins. - Basic research and clinical perspectives -. , 2010, Circulation journal : official journal of the Japanese Circulation Society.
[79] H. Cao,et al. Comparison of Effects of Simvastatin Versus Atorvastatin on Oxidative Stress in Patients With Coronary Heart Disease , 2010, Clinical cardiology.
[80] C. Bonfils,et al. Cyclophilin A as negative regulator of apoptosis by sequestering cytochrome c. , 2010, Biochemical and biophysical research communications.
[81] Yiannis S. Chatzizisis,et al. Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy , 2010, Drug safety.
[82] V. Shoshan-Barmatz,et al. NCLX is an essential component of mitochondrial Na+/Ca2+ exchange , 2009, Proceedings of the National Academy of Sciences.
[83] P. Pasdois,et al. The role of the mitochondrial permeability transition pore in heart disease. , 2009, Biochimica et biophysica acta.
[84] T. Gunter,et al. Characteristics and possible functions of mitochondrial Ca(2+) transport mechanisms. , 2009, Biochimica et biophysica acta.
[85] G. Ginsburg,et al. The SLCO1B1*5 genetic variant is associated with statin-induced side effects. , 2009, Journal of the American College of Cardiology.
[86] H. Bonkovsky,et al. Drug-Induced Liver Injury Associated with Statins , 2009, Seminars in liver disease.
[87] A. Vercesi,et al. Mitochondria and reactive oxygen species. , 2009, Free radical biology & medicine.
[88] Ignazio Grattagliano,et al. Current Concepts of Mechanisms in Drug-Induced Hepatotoxicity , 2009, Current medicinal chemistry.
[89] M. Quon,et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. , 2009, Atherosclerosis.
[90] D. Steinberg. The LDL modification hypothesis of atherogenesis: an update Published, JLR Papers in Press, November 15, 2009. , 2009, Journal of Lipid Research.
[91] E. Hall,et al. Comparative Neuroprotective Effects of Cyclosporin a and NIM811, a Nonimmunosuppressive Cyclosporin a Analog, following Traumatic Brain Injury , 2009, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.
[92] R. Fontana,et al. Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. , 2008, Gastroenterology.
[93] A. Vercesi,et al. Simvastatin inducing PC3 prostate cancer cell necrosis mediated by calcineurin and mitochondrial dysfunction , 2008, Journal of bioenergetics and biomembranes.
[94] A. Heidland,et al. Rosuvastatin protects against oxidative stress and DNA damage in vitro via upregulation of glutathione synthesis. , 2008, Atherosclerosis.
[95] A. Lonardo,et al. Statins in liver disease: A molehill, an iceberg, or neither? , 2008, Hepatology.
[96] T. Ajith,et al. IN VITRO ANTI‐OXIDANT AND DNA PROTECTIVE EFFECTS OF THE NOVEL 3‐HYDROXY‐3‐METHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR ROSUVASTATIN , 2008, Clinical and experimental pharmacology & physiology.
[97] A. Vercesi,et al. Oxidative stress in hypercholesterolemic LDL (low-density lipoprotein) receptor knockout mice is associated with low content of mitochondrial NADP-linked substrates and is partially reversed by citrate replacement. , 2008, Free radical biology & medicine.
[98] A. M. Marsden,et al. Rosuvastatin: Characterization of Induced Myopathy in the Rat , 2008, Toxicologic pathology.
[99] Xìao-chun Xu,et al. Statin Induces Apoptosis and Cell Growth Arrest in Prostate Cancer Cells , 2008, Cancer Epidemiology Biomarkers & Prevention.
[100] H. Mabuchi,et al. Effects of CoQ10 supplementation on plasma lipoprotein lipid, CoQ10 and liver and muscle enzyme levels in hypercholesterolemic patients treated with atorvastatin: a randomized double-blind study. , 2007, Atherosclerosis.
[101] James H. Lewis,et al. Efficacy and safety of high‐dose pravastatin in hypercholesterolemic patients with well‐compensated chronic liver disease: Results of a prospective, randomized, double‐blind, placebo‐controlled, multicenter trial , 2007, Hepatology.
[102] Joanna M. Young,et al. Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia. , 2007, The American journal of cardiology.
[103] K. Jeyaseelan,et al. Reduced mitochondrial coenzyme Q10 levels in HepG2 cells treated with high-dose simvastatin: a possible role in statin-induced hepatotoxicity? , 2007, Toxicology and Applied Pharmacology.
[104] Gian Paolo Littarru,et al. Bioenergetic and Antioxidant Properties of Coenzyme Q10: Recent Developments , 2007, Molecular biotechnology.
[105] N. Chalasani,et al. Lipid-lowering agents that cause drug-induced hepatotoxicity. , 2007, Clinics in liver disease.
[106] Michalis V. Karamouzis,et al. Post-translational modifications and regulation of the RAS superfamily of GTPases as anticancer targets , 2007, Nature Reviews Drug Discovery.
[107] P. Thompson,et al. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. , 2007, Journal of the American College of Cardiology.
[108] G. Littarru,et al. Coenzyme Q10 and statins: biochemical and clinical implications. , 2007, Mitochondrion.
[109] M. McNurlan,et al. Effect of coenzyme q10 on myopathic symptoms in patients treated with statins. , 2007, The American journal of cardiology.
[110] R. Radi,et al. Inactivation and nitration of human superoxide dismutase (SOD) by fluxes of nitric oxide and superoxide. , 2007, Free radical biology & medicine.
[111] T. Lehtimäki,et al. Decreased Skeletal Muscle Mitochondrial DNA in Patients Treated with High‐Dose Simvastatin , 2007, Clinical pharmacology and therapeutics.
[112] Takayuki Takahashi,et al. Protective Effects of Coenzyme Q10 on Decreased Oxidative Stress Resistance Induced by Simvastatin , 2007, Journal of clinical biochemistry and nutrition.
[113] Yoshiyuki Tanaka,et al. Simvastatin reduces insulin-like growth factor-1 signaling in differentiating C2C12 mouse myoblast cells in an HMG-CoA reductase inhibition-independent manner. , 2007, The Journal of toxicological sciences.
[114] Oliver Holub,et al. Mitochondrial Creatine Kinase Activity Prevents Reactive Oxygen Species Generation , 2006, Journal of Biological Chemistry.
[115] C. Sirtori,et al. Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study , 2006, British journal of pharmacology.
[116] A. Vercesi,et al. Hyperlipidemic mice present enhanced catabolism and higher mitochondrial ATP-sensitive K+ channel activity. , 2006, Gastroenterology.
[117] J. Mckenney. An assessment of statin safety. , 2006, The American journal of managed care.
[118] S. Krähenbühl,et al. Toxicity of statins on rat skeletal muscle mitochondria , 2006, Cellular and Molecular Life Sciences CMLS.
[119] A. Vercesi,et al. Mitochondrial Ca2+ transport, permeability transition and oxidative stress in cell death: implications in cardiotoxicity, neurodegeneration and dyslipidemias. , 2006, Frontiers in bioscience : a journal and virtual library.
[120] H. Hoppeler,et al. Statin therapy induces ultrastructural damage in skeletal muscle in patients without myalgia , 2006, The Journal of pathology.
[121] M. Nakata,et al. Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control , 2006, Diabetologia.
[122] Fabio Di Lisa,et al. The mitochondrial permeability transition from in vitro artifact to disease target , 2006, The FEBS journal.
[123] J. Rydström. Mitochondrial NADPH, transhydrogenase and disease. , 2006, Biochimica et biophysica acta.
[124] N. Chalasani,et al. An assessment of statin safety by hepatologists. , 2006, The American journal of cardiology.
[125] S. Ye,et al. Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents. , 2006, The American journal of pathology.
[126] C. Cleeland,et al. The role of statins in cancer therapy. , 2006, The oncologist.
[127] A. Vercesi,et al. Statins induce calcium-dependent mitochondrial permeability transition. , 2006, Toxicology.
[128] H. B. Levy,et al. Considerations for Supplementing with Coenzyme Q10 During Statin Therapy , 2006, The Annals of pharmacotherapy.
[129] I. Gülçin. Antioxidant and antiradical activities of L-carnitine. , 2006, Life sciences.
[130] M. Yüksel,et al. Effects of statins on experimental colitis in normocholesterolemic rats , 2006, Scandinavian journal of gastroenterology.
[131] Todd Sherer,et al. Rotenone Model of Parkinson Disease , 2005, Journal of Biological Chemistry.
[132] K. Criswell,et al. Roles of exercise and pharmacokinetics in cerivastatin-induced skeletal muscle toxicity. , 2005, Toxicological sciences : an official journal of the Society of Toxicology.
[133] E. Bruckert,et al. Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.
[134] Stephen B. Gruber,et al. Statins and cancer prevention , 2005, Nature Reviews Cancer.
[135] C. Heyningen. Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe , 2005 .
[136] O. Henriksen,et al. Statin‐associated myopathy with normal creatine kinase levels , 2005 .
[137] R. Andrade,et al. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. , 2005, Gastroenterology.
[138] T. Lehtimäki,et al. High‐dose statins and skeletal muscle metabolism in humans: A randomized, controlled trial , 2005, Clinical pharmacology and therapeutics.
[139] B. Wong,et al. Muscle coenzyme Q: a potential test for mitochondrial activity and redox status. , 2005, Pediatric neurology.
[140] P. Sirvent,et al. Simvastatin triggers mitochondria-induced Ca2+ signaling alteration in skeletal muscle. , 2005, Biochemical and biophysical research communications.
[141] N. Chalasani. Statins and hepatotoxicity: Focus on patients with fatty liver , 2005, Hepatology.
[142] Jayoung Kim,et al. Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts. , 2005, The Journal of clinical investigation.
[143] A. Vercesi,et al. Oxidative stress in atherosclerosis‐prone mouse is due to low antioxidant capacity of mitochondria , 2005, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[144] A. M. Marsden,et al. Statin-Induced Muscle Necrosis in the Rat: Distribution, Development, and Fibre Selectivity , 2005, Toxicologic pathology.
[145] B. Psaty,et al. Potential for Conflict of Interest in the Evaluation of Suspected Adverse Drug Reactions: Use of Cerivastatin and Risk of Rhabdomyolysis , 2004 .
[146] A. Vercesi,et al. Redox State of Endogenous Coenzyme Q Modulates the Inhibition of Linoleic Acid-Induced Uncoupling by Guanosine Triphosphate in Isolated Skeletal Muscle Mitochondria , 2004, Journal of bioenergetics and biomembranes.
[147] G. Fiskum,et al. Mitochondrial calcium and oxidative stress as mediators of ischemic brain injury. , 2004, Cell calcium.
[148] D. Souza,et al. Mitochondrial permeability transition in neuronal damage promoted by Ca2+ and respiratory chain complex II inhibition , 2004, Journal of neurochemistry.
[149] S. Dimauro,et al. Atorvastatin decreases the coenzyme Q10 level in the blood of patients at risk for cardiovascular disease and stroke. , 2004, Archives of neurology.
[150] A. Goldberg,et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. , 2004, Mayo Clinic proceedings.
[151] L. Lemberg,et al. Statin pleiotropy: fact or fiction? , 2004, American journal of critical care : an official publication, American Association of Critical-Care Nurses.
[152] A. M. James,et al. Antioxidant and prooxidant properties of mitochondrial Coenzyme Q. , 2004, Archives of biochemistry and biophysics.
[153] D. Hilgemann,et al. Multiple transport modes of the cardiac Na+/Ca2+ exchanger , 2004, Nature.
[154] G. Dallner,et al. Metabolism and function of coenzyme Q. , 2004, Biochimica et biophysica acta.
[155] J. Turrens,et al. Mitochondrial formation of reactive oxygen species , 2003, The Journal of physiology.
[156] M. Berridge,et al. Calcium signalling: dynamics, homeostasis and remodelling , 2003, Nature reviews. Molecular cell biology.
[157] J. Tobert,et al. Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors , 2003, Nature Reviews Drug Discovery.
[158] E. Toma,et al. Statin-associated myopathy with normal creatine kinase levels. , 2003, Annals of internal medicine.
[159] Sarah Parish,et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial , 2003, The Lancet.
[160] T. Wallimann,et al. Inhibition of the Mitochondrial Permeability Transition by Creatine Kinase Substrates , 2003, The Journal of Biological Chemistry.
[161] K. Reddy,et al. Hepatotoxicity of hypolipidemic drugs. , 2003, Clinics in liver disease.
[162] R. Suresh,et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. , 2003, European heart journal.
[163] J. England,et al. Statin-Associated Myopathy with Normal Creatine Kinase Levels , 2002, Annals of Internal Medicine.
[164] M. Evans,et al. The myotoxicity of statins. , 2002 .
[165] P. Stiefel,et al. Simvastatin improves endothelial function in spontaneously hypertensive rats through a superoxide dismutase mediated antioxidant effect , 2002, Journal of hypertension.
[166] U. Laufs,et al. Cellular Antioxidant Effects of Atorvastatin In Vitro and In Vivo , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[167] J. Lawler,et al. Direct antioxidant properties of creatine. , 2002, Biochemical and biophysical research communications.
[168] Su-Min Lee,et al. Control of Mitochondrial Redox Balance and Cellular Defense against Oxidative Damage by Mitochondrial NADP+-dependent Isocitrate Dehydrogenase* , 2001, The Journal of Biological Chemistry.
[169] A E Vercesi,et al. Mitochondrial permeability transition and oxidative stress , 2001, FEBS letters.
[170] A. Vercesi,et al. Bcl-2 prevents mitochondrial permeability transition and cytochrome c release via maintenance of reduced pyridine nucleotides , 2000, Cell Death and Differentiation.
[171] M. Wyss,et al. Creatine and creatinine metabolism. , 2000, Physiological reviews.
[172] K. Tolman,et al. Defining patient risks from expanded preventive therapies. , 2000, The American journal of cardiology.
[173] F. L. Crane,et al. Interactions Between Ascorbyl Free Radical and Coenzyme Q at the Plasma Membrane , 2000, Journal of bioenergetics and biomembranes.
[174] A. Kowaltowski. Alternative mitochondrial functions in cell physiopathology: beyond ATP production. , 2000, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[175] A. Vercesi,et al. Ca2+-induced increased lipid packing and domain formation in submitochondrial particles. A possible early step in the mechanism of Ca2+-stimulated generation of reactive oxygen species by the respiratory chain. , 1999, Biochemistry.
[176] D R Pearson,et al. Performance and muscle fiber adaptations to creatine supplementation and heavy resistance training. , 1999, Medicine and science in sports and exercise.
[177] B. Foster,et al. Role of RhoA activation in the growth and morphology of a murine prostate tumor cell line , 1999, Oncogene.
[178] C. Sempoux,et al. Ator vastatin-induced acute hepatitis with absence of cross-toxicity with simvastatin , 1999, The Lancet.
[179] M. Nishikawa,et al. Effect of Treatment with 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase Inhibitors on Serum Coenzyme Q10 in Diabetic Patients , 1999, Arzneimittelforschung.
[180] A. Vercesi,et al. Mitochondrial damage induced by conditions of oxidative stress. , 1999, Free radical biology & medicine.
[181] E. Laws,et al. A phase I-II trial of lovastatin for anaplastic astrocytoma and glioblastoma multiforme. , 1998, American journal of clinical oncology.
[182] J. Mccombs,et al. Factors affecting patient compliance with antihyperlipidemic medications in an HMO population. , 1998, The American journal of managed care.
[183] D. Brenner,et al. The mitochondrial permeability transition in cell death: a common mechanism in necrosis, apoptosis and autophagy. , 1998, Biochimica et biophysica acta.
[184] Lawrence M. Lifshitz,et al. Close contacts with the endoplasmic reticulum as determinants of mitochondrial Ca2+ responses. , 1998, Science.
[185] Anibal E. Vercesi,et al. The Thiol-specific Antioxidant Enzyme Prevents Mitochondrial Permeability Transition , 1998, The Journal of Biological Chemistry.
[186] Bruce R. Rosen,et al. Neuroprotective Effects of Creatine and Cyclocreatine in Animal Models of Huntington’s Disease , 1998, The Journal of Neuroscience.
[187] A. Kowaltowski,et al. Ca2+ acting at the external side of the inner mitochondrial membrane can stimulate mitochondrial permeability transition induced by phenylarsine oxide. , 1997, Biochimica et biophysica acta.
[188] V. Skulachev,et al. High protonic potential actuates a mechanism of production of reactive oxygen species in mitochondria , 1997, FEBS letters.
[189] A. Vercesi,et al. The Role of Reactive Oxygen Species in Mitochondrial Permeability Transition , 1997, Bioscience reports.
[190] A. Vercesi,et al. The irreversibility of inner mitochondrial membrane permeabilization by Ca2+ plus prooxidants is determined by the extent of membrane protein thiol cross-linking , 1996, Journal of bioenergetics and biomembranes.
[191] E. Wang,et al. Bcl-2 potentiates the maximal calcium uptake capacity of neural cell mitochondria. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[192] D. Samid,et al. Phase I study of lovastatin, an inhibitor of the mevalonate pathway, in patients with cancer. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.
[193] J. Drapier,et al. Modulation of Iron Regulatory Protein Functions , 1996, The Journal of Biological Chemistry.
[194] A. Vercesi,et al. Opening of the mitochondrial permeability transition pore by uncoupling or inorganic phosphate in the presence of Ca2+ is dependent on mitochondrial‐generated reactive oxygen species , 1996, FEBS letters.
[195] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia , 1995 .
[196] A. Vercesi,et al. Ca(2+)-induced mitochondrial membrane permeabilization: role of coenzyme Q redox state. , 1995, The American journal of physiology.
[197] G. Dallner,et al. Biochemical, physiological and medical aspects of ubiquinone function. , 1995, Biochimica et biophysica acta.
[198] R. Platt,et al. Discontinuation of antihyperlipidemic drugs--do rates reported in clinical trials reflect rates in primary care settings? , 1995, The New England journal of medicine.
[199] R. Gregg,et al. In vitro myotoxicity of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, pravastatin, lovastatin, and simvastatin, using neonatal rat skeletal myocytes. , 1995, Toxicology and applied pharmacology.
[200] Etelvino J. H. Bechara,et al. Permeabilization of the inner mitochondrial membrane by Ca2+ ions is stimulated by t-butyl hydroperoxide and mediated by reactive oxygen species generated by mitochondria. , 1995, Free radical biology & medicine.
[201] R. Laaksonen,et al. Decreases in serum ubiquinone concentrations do not result in reduced levels in muscle tissue during short‐term simvastatin treatment in humans , 1995, Clinical pharmacology and therapeutics.
[202] T. Yada,et al. Cytosolic Ca2+ increase and cell damage in L6 rat myoblasts by HMG-CoA reductase inhibitors. , 1994, Biochemical and biophysical research communications.
[203] J. Meldolesi,et al. Molecular and cellular physiology of intracellular calcium stores. , 1994, Physiological reviews.
[204] A. Vercesi,et al. The participation of reactive oxygen species and protein thiols in the mechanism of mitochondrial inner membrane permeabilization by calcium plus prooxidants. , 1993, Archives of biochemistry and biophysics.
[205] T. Pozzan,et al. Microdomains with high Ca2+ close to IP3-sensitive channels that are sensed by neighboring mitochondria. , 1993, Science.
[206] D. Flint,et al. The inactivation of Fe-S cluster containing hydro-lyases by superoxide. , 1993, The Journal of biological chemistry.
[207] A. Engel,et al. Experimental Lovastatin Myopathy , 1993, Journal of neuropathology and experimental neurology.
[208] R. Hammer,et al. Hypercholesterolemia in low density lipoprotein receptor knockout mice and its reversal by adenovirus-mediated gene delivery. , 1993, The Journal of clinical investigation.
[209] G. Littarru,et al. Evidence of Plasma CoQ10‐Lowering Effect by HMG‐CoA Reductase Inhibitors: A Double‐Blind, Placebo‐Controlled Study , 1993, Journal of clinical pharmacology.
[210] G. Dallner,et al. Effects of mevinolin treatment on tissue dolichol and ubiquinone levels in the rat. , 1992, Biochimica et biophysica acta.
[211] L. Ji,et al. Glutathione and antioxidant enzymes in skeletal muscle: effects of fiber type and exercise intensity. , 1992, Journal of applied physiology.
[212] A. Endo,et al. The discovery and development of HMG-CoA reductase inhibitors. , 1992, Journal of lipid research.
[213] D. Leake,et al. The oxidative modification of low density lipoprotein by human lymphocytes. , 1992, Atherosclerosis.
[214] J. Crapo,et al. Detection of catalase in rat heart mitochondria. , 1991, The Journal of biological chemistry.
[215] A. Vercesi,et al. Membrane protein thiol cross-linking associated with the permeabilization of the inner mitochondrial membrane by Ca2+ plus prooxidants. , 1990, The Journal of biological chemistry.
[216] J. Goldstein,et al. Regulation of the mevalonate pathway , 1990, Nature.
[217] A. Vercesi,et al. Ca2+ transport by coupled Trypanosoma cruzi mitochondria in situ. , 1989, The Journal of biological chemistry.
[218] S. Prahalada,et al. Preclinical evaluation of lovastatin. , 1988, The American journal of cardiology.
[219] D. Morel,et al. Endothelial and Smooth Muscle Cells Alter Low Density Lipoprotein In Vitro by Free Radical Oxidation , 1984, Arteriosclerosis.
[220] R Monaghan,et al. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. , 1980, Proceedings of the National Academy of Sciences of the United States of America.
[221] Endo Akira,et al. Effects of ML-236B on cholesterol metabolism in mice and rats: Lack of hypocholesterolemic activity in normal animals , 1979 .
[222] A. Endo. Monacolin K, a new hypocholesterolemic agent produced by a Monascus species. , 1979, The Journal of antibiotics.
[223] M. Brown,et al. Receptor-mediated endocytosis: insights from the lipoprotein receptor system. , 1979, Proceedings of the National Academy of Sciences of the United States of America.
[224] A. Lehninger,et al. Regulation of Ca2+ release from mitochondria by the oxidation-reduction state of pyridine nucleotides. , 1978, Proceedings of the National Academy of Sciences of the United States of America.
[225] Endo Akira,et al. Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by the antibiotic citrinin. , 1977 .
[226] R. Haworth,et al. Relationship between configuration, function, and permeability in calcium-treated mitochondria. , 1976, The Journal of biological chemistry.
[227] M. Kuroda,et al. Citrinin, an inhibitor of cholesterol synthesis. , 1976, The Journal of antibiotics.
[228] Joseph L. Goldstein,et al. Familial hypercholesterolemia: Defective binding of lipoproteins to cultured fibroblasts associated with impaired regulation of 3-hydroxy-3-methylglutaryl coenzyme a reductase activity , 1974, Proceedings of the National Academy of Sciences.
[229] J. H. Globus,et al. JOURNAL of NEUROPATHOLOGY and EXPERIMENTAL NEUROLOGY , 1969 .
[230] F. D. Vasington,et al. Ca ion uptake by rat kidney mitochondria and its dependence on respiration and phosphorylation. , 1962, The Journal of biological chemistry.
[231] H. DeLuca,et al. Calcium uptake by rat kidney mitochondria. , 1961, Proceedings of the National Academy of Sciences of the United States of America.
[232] P. Mitchell. Coupling of Phosphorylation to Electron and Hydrogen Transfer by a Chemi-Osmotic type of Mechanism , 1961, Nature.
[233] G. Watts,et al. Pathogenesis and Management of the Diabetogenic Effect of Statins: a Role for Adiponectin and Coenzyme Q10? , 2014, Current Atherosclerosis Reports.
[234] P. Neufer,et al. Simvastatin impairs ADP-stimulated respiration and increases mitochondrial oxidative stress in primary human skeletal myotubes. , 2012, Free radical biology & medicine.
[235] C. White,et al. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. , 2010, Diabetes research and clinical practice.
[236] Hiroyasu Ito,et al. Statin-induced Ca(2+) release was increased in B lymphocytes in patients who showed elevated serum creatine kinase during statin treatment. , 2009, Journal of atherosclerosis and thrombosis.
[237] D. Harnois. Causes, Clinical Features, and Outcomes From a Prospective Study of Drug-Induced Liver Injury in the United States , 2009 .
[238] A. Vercesi,et al. Mitochondrial Energy Metabolism and Redox State in Dyslipidemias , 2007, IUBMB life.
[239] Lorenzo Galluzzi,et al. Mitochondrial membrane permeabilization in cell death. , 2007, Physiological reviews.
[240] W. H. Schaefer,et al. Evaluation of ubiquinone concentration and mitochondrial function relative to cerivastatin-induced skeletal myopathy in rats. , 2004, Toxicology and applied pharmacology.
[241] A. Federico,et al. Mitochondrial alterations in muscle biopsies of patients on statin therapy. , 2004, Journal of submicroscopic cytology and pathology.
[242] A. Gotto,et al. The evolving role of statins in the management of atherosclerosis. , 2000, Journal of the American College of Cardiology.
[243] A. De Luca,et al. Effects of HMG-CoA reductase inhibitors on excitation-contraction coupling of rat skeletal muscle. , 1999, European journal of pharmacology.
[244] M. Marcelli,et al. Caspase-7 is activated during lovastatin-induced apoptosis of the prostate cancer cell line LNCaP. , 1998, Cancer research.
[245] F. L. Crane,et al. The diversity of coenzyme Q function. , 1997, Molecular aspects of medicine.
[246] A. Vercesi,et al. Oxidative damage of mitochondria induced by Fe(II)citrate or t-butyl hydroperoxide in the presence of Ca2+: effect of coenzyme Q redox state. , 1995, Free radical biology & medicine.
[247] P. Macfarlane,et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. , 1995, The New England journal of medicine.
[248] I. Fridovich,et al. Superoxide radical and superoxide dismutases. , 1995, Annual review of biochemistry.
[249] L. Packer,et al. Interactions between ubiquinones and vitamins in membranes and cells. , 1994, Molecular aspects of medicine.
[250] R. Radi,et al. Inhibition of mitochondrial electron transport by peroxynitrite. , 1994, Archives of biochemistry and biophysics.
[251] A. Vercesi,et al. NADP redox state and mitochondrial Ca2+ efflux: a controversial issue. , 1984, Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas.
[252] Y. Tsujita,et al. Effects of ML-236B on cholesterol metabolism in mice and rats: lack of hypocholesterolemic activity in normal animals. , 1979, Biochimica et biophysica acta.
[253] M. Kuroda,et al. Time-dependent, irreversible inhibition of 3-hydroxy-3-methylglutaryl-coenzyme A reductase by the antibiotic citrinin. , 1977, Biochimica et biophysica acta.
[254] 原 一郎. Journal of Lipid Researchの発刊について , 1960 .
[255] M. Duchen,et al. Annals of the New York Academy of Sciences Calcium Signaling as a Mediator of Cell Energy Demand and a Trigger to Cell Death , 2022 .